Alcobra Ltd. (ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder, visited the NASDAQ MarketSite in Times Square to celebrate its recent initial public offering (IPO), which occurred on May 22, 2013.
6 weeks after IPO
No comments:
Post a Comment